US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

8.83

-0.3200-3.50%

Post-market: 8.830.00000.00%19:30 EDT

Volume:495.36K

Turnover:4.40M

Market Cap:490.73M

PE:-1.75

High:9.42

Open:9.15

Low:8.70

Close:9.15

52wk High:40.43

52wk Low:8.70

Shares:55.58M

Float Shares:19.23M

Volume Ratio:1.36

T/O Rate:2.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.41

PE(LYR):-0.48

Loading ...

Overview Company News Filings

MapLight Shareholders Back Board Slate and Auditor

Maplight Therapeutics Shareholders Elect Three Directors at Annual Meeting

Maplight Therapeutics Names Martin Babler, Troy Cox to Board of Directors

Maplight Therapeutics Announces Changes to Board of Directors

THOMSON REUTERS

Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)

Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained

MapLight Therapeutics Is Maintained at Buy by Needham

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)

BUZZ-Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss

MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit

MapLight says Phase 2 IRIS trial of ML-004 in autism misses primary endpoint

Maplight Therapeutics - Ml-004 Generally Well-Tolerated With No Severe or Serious Adverse Events in Phase 2 IRIS Trial

THOMSON REUTERS

Maplight Therapeutics - Phase 2 IRIS Trial Does Not Meet Primary Endpoint in Asd

THOMSON REUTERS

Maplight Therapeutics - to Engage With FDA in End-of-Phase 2 Meeting for Ml-004

THOMSON REUTERS

Maplight Announces Topline Results From Phase 2 IRIS Study for Ml-004 in Autism Spectrum Disorder

THOMSON REUTERS

Maplight Therapeutics Inc: Setia Is Not Entitled to Receive Any Severance Payment in Connection With His Separation

THOMSON REUTERS

Maplight Therapeutics - Jonathan Gillis to Continue as Principal Accounting Officer - SEC Filing

THOMSON REUTERS

Maplight Therapeutics - Vishwas Setia Separated as CFO Effective Immediately on June 18, 2026 - SEC Filing

THOMSON REUTERS

MapLight Therapeutics names Jonathan Gillis interim CFO after Vishwas Setia exit

MapLight Therapeutics Is Maintained at Buy by Stifel

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MPLT/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":8.83,"timestamp":1791576000000,"preClose":9.15,"halted":0,"volume":495355,"hourTrading":{"tag":"盘后","latestPrice":8.83,"preClose":8.83,"latestTime":"19:30 EDT","volume":2389,"amount":21106.17,"timestamp":1791588606185,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03497267759562844,"floatShares":19234500,"shares":55575700,"eps":-5.058,"marketStatus":"Market Closed","change":-0.32,"latestTime":"10-09 16:00:00 EDT","open":9.15,"high":9.415,"low":8.7,"amount":4396009.619365,"amplitude":0.078142,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":9.15,"preHourTrading":{"tag":"盘前","latestPrice":9.69,"preClose":9.15,"latestTime":"08:59 EDT","volume":66,"amount":613.670046,"timestamp":1791550796981,"change":0.54,"changeRate":0.059016,"amplitude":0.057923},"postHourTrading":{"tag":"盘后","latestPrice":8.83,"preClose":8.83,"latestTime":"19:30 EDT","volume":2389,"amount":21106.17,"timestamp":1791588606185,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3636488768783048,"impliedVol":0.9887,"impliedVolPercentile":0.3333},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":19234500,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":1.3636488768783048,"shares":55575700,"dividePrice":0,"high":9.415,"amplitude":0.078142,"preClose":9.15,"low":8.7,"week52Low":8.7,"pbRate":"1.41","week52High":40.43,"institutionHeld":0,"latestPrice":8.83,"eps":-5.058,"divideRate":0,"volume":495355,"delay":0,"ttmEps":-5.058,"open":9.15,"prevYearClose":17.565,"prevWeekClose":9.82,"prevMonthClose":10.19,"prevQuarterClose":10.19,"fiveDayClose":9.82,"twentyDayClose":13,"sixtyDayClose":37.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-10-09","current":-1.745749,"percent":1,"low":-9.047313,"twenty":-8.011778,"median":-7.261334,"eighty":-3.2766,"high":-2.212611,"avg":-6.406557,"sd":2.079588,"marketCap":508517828},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-09-04","current":-3.177455,"twenty":-8.055812,"median":-7.370362,"eighty":-6.26295,"marketCap":730264947},{"date":"2026-09-11","current":-3.333426,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"marketCap":766111286},{"date":"2026-09-18","current":-2.737351,"twenty":-8.049665,"median":-7.312639,"eighty":-6.03858,"marketCap":629117139},{"date":"2026-09-25","current":-2.601934,"twenty":-8.035579,"median":-7.308017,"eighty":-5.386392,"marketCap":597994736},{"date":"2026-10-02","current":-2.328683,"twenty":-8.020709,"median":-7.275626,"eighty":-3.397933,"marketCap":535194173},{"date":"2026-10-09","current":-2.212611,"twenty":-8.011778,"median":-7.261334,"eighty":-3.2766,"marketCap":508517828}],"updateTime":1791642535402},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645189085","title":"MapLight Shareholders Back Board Slate and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2645189085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645189085?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:28","pubTimestamp":1782300504,"startTime":"0","endTime":"0","summary":"An announcement from MapLight Therapeutics, Inc. ( ($MPLT) ) is now available. On June 23, 2026, MapLight Therapeutics stockholders held their 2026...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maplight-shareholders-back-board-slate-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maplight-shareholders-back-board-slate-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897327","title":"Maplight Therapeutics Shareholders Elect Three Directors at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897327?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:15","pubTimestamp":1782299741,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics shareholders elect three directors at annual meetingMaplight Therapeutics held its annual stockholder meeting on June 23, 2026.Stockholders backed the selection of RSM US LLP as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDLTxGJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645089221","title":"Maplight Therapeutics Names Martin Babler, Troy Cox to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645089221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645089221?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:01","pubTimestamp":1782298911,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics names Martin Babler, Troy Cox to board of directorsMapLight Therapeutics added Martin Babler and Troy Cox to its board following their election at the June 23 annual meeting.Babl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL4dzdNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4007","SG9999014021.USD","BK4139","SG9999014039.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","NDAQ","BK4112","BK4585","ALMS","SG9999014013.SGD","BK4588","MPLT","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645892144","title":"Maplight Therapeutics Announces Changes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645892144","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645892144?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:00","pubTimestamp":1782298801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7ZV0DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839227","title":"Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839227?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:55","pubTimestamp":1782219353,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum maintained a Buy rating on MapLight Therapeutics, Inc., with a price target of $40.00. Vog...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835890","title":"Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835890?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:28","pubTimestamp":1782214104,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman reiterated a Buy rating on MapLight Therapeutics, Inc. yesterday and set a price target of $34.00. Sean Laaman h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/overweight-rating-reaffirmed-on-ml004s-irritability-efficacy-and-safety-profile-34-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/overweight-rating-reaffirmed-on-ml004s-irritability-efficacy-and-safety-profile-34-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645716200","title":"MapLight Therapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2645716200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645716200?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:36","pubTimestamp":1782149760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 13:36 ET (17:36 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645607190","title":"Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645607190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645607190?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:20","pubTimestamp":1782148814,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and MapLight Therapeutics, Inc. (MPLT)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbvie-abbv-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbvie-abbv-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2347655156.SGD","LU0124676726.USD","LU0211327993.USD","LU0965509010.AUD","LU2237443382.USD","LU0795875086.SGD","LU1267930490.SGD","LU0256863811.USD","LU1732799900.SGD","LU2089283258.USD","LU0861579265.USD","LU1291159041.SGD","LU2129689605.HKD","LU0965508806.USD","BK4581","IE000F7OJYX1.SGD","LU0661504455.SGD","LU1430594728.SGD","IE00B3PB1722.GBP","IE00B19Z3581.USD","LU2087621335.USD","IE0000B7K699.USD","LU2023251221.USD","IE00BN8TJ469.HKD","LU1003077747.HKD","LU1244550494.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU2237443549.SGD","IE0002141913.USD","LU0820561909.HKD","LU2129689514.USD","LU0965509101.SGD","IE0009355771.USD","LU1839511570.USD","LU1093756168.USD","IE00BSNM7G36.USD","BK4588","LU0859254822.USD","LU0320765646.SGD","LU1585245621.USD","LU0122379950.USD","LU0689626769.HKD","LU2357627491.SGD","BK4533","IE00BJJMRZ35.SGD","LU0029864427.USD","LU0198837287.USD","LU1057294990.SGD","LU1267930573.SGD","ABBV","IE00BFTCPJ56.SGD","LU0708994859.HKD","LU0170899867.USD","LU0289739343.SGD","SG9999015986.USD","LU0310800379.SGD","LU1934455277.USD","LU1929549753.HKD","LU0472753341.HKD","LU2112291526.USD","IE00BLSP4452.SGD","LU1732800096.USD","IE00B42XCP33.USD","LU2237443978.SGD","LU0985320562.USD","LU0882574055.USD","LU2089984988.USD","BK4550","IE00B2B36J28.USD","LU1037948541.HKD","LU0234572021.USD","IE0002270589.USD","LU1670627923.USD","LU0868494617.USD","LU0942090050.USD","LU1023059063.AUD","LU1162221912.USD","LU0545039389.USD","SG9999001440.SGD","LU1989772840.SGD","LU0738911758.USD","LU1093756325.SGD","LU2237443895.HKD","LU1989772923.USD","LU0234570918.USD","LU0912757837.SGD","LU0256863902.USD","LU1551013425.SGD","MPLT","LU1670628061.USD","LU1718418525.SGD","LU2133065610.SGD","IE000WAW04H5.SGD","LU0820561818.USD","LU0310799852.SGD","LU0965509283.SGD","LU0511384066.AUD","IE00BVYPNW00.USD","LU1061106388.HKD","LU0417517546.SGD","LU2237443622.USD","LU2237443465.HKD","LU0128525929.USD","SG9999015952.SGD","LU0456855351.SGD","BK4534","IE000BZT7R73.USD","LU0949170772.SGD","LU1496350502.SGD","LU1934455863.HKD","IE00BGHQF631.EUR","LU0158827948.USD","LU0289739699.SGD","LU0211328371.USD","LU0943347566.SGD","LU1244550577.SGD","LU1551013342.USD","IE000SO60NU8.SGD","LU0289961442.SGD","LU0203347892.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0689472784.USD","SG9999015945.SGD","LU1983299246.USD","LU2468319806.SGD","LU0823416689.USD","LU1244550221.USD","BK4585","IE00BDGV0183.EUR","LU0069063385.USD","LU1989771016.USD","SG9999011175.SGD","LU0203345920.USD","LU0057025933.USD","LU1934455194.USD","BK4566","IE000MB6IJN5.SGD","IE00B4R5TH58.HKD","SG9999003800.SGD","LU0432979614.USD","LU0868494708.USD","LU1496350171.SGD","LU1037948897.HKD","LU0795875169.SGD","LU1074936037.SGD","IE00BJT1NW94.SGD","LU0058720904.USD","IE00BVYPNV92.GBP","BK4559","LU0098860793.USD","LU2089284900.SGD","BK4139","SG9999015978.USD","IE0004445239.USD","LU2129689431.USD","LU0553294199.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645730230","title":"BUZZ-Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2645730230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645730230?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:53","pubTimestamp":1782140005,"startTime":"0","endTime":"0","summary":"BUZZ-Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss** Shares of Maplight Therapeutics MPLT.O rise 6.8% to $30.79** Co says its autism drug, ML-004, did not improve social communication after 12 weeks, missing its main goal in a mid-stage trial ** \"We'd argue this indication had low Street expectations prior to the readout,\" Jefferies analyst Andrew Tsai said** However, in a pre-specified analysis of small group of adolescents with moderate to severe irritability, the drug produced a large reduction in irritability symptoms compared to placebo, with an effect size of 1.33 described as \"clinically meaningful\"** \"While the primary endpoint missed, ML-004 showed a clinically meaningful signal in irritability among adolescents with moderate or greater baseline irritability, a setting with an established regulatory path and meaningful unmet need,\" TD Cowen analyst Joseph Thome says** Co plans to meet U.S. FDA to discuss next steps for development focuse","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645162024","title":"MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2645162024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645162024?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:59","pubTimestamp":1782129540,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents.The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial.The company noted that an approved pharmacologic therapy for social communication currently doesn't exist.However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options.MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645934029","title":"MapLight says Phase 2 IRIS trial of ML-004 in autism misses primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2645934029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645934029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126058,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics reported topline Phase 2 IRIS results for ML-004 in autism spectrum disorder; findings were presented with the announcement.The trial missed its primary goal on social communication, raising uncertainty for the program’s initial development thesis.A prespecified adolescent subgroup with higher baseline irritability showed meaningful improvement versus placebo, supporting a potential pivot toward that symptom domain.ML-004 was generally well tolerated, with no severe or serious adverse events reported in the active-treatment arm.Maplight plans an FDA End-of-Phase 2 meeting to determine next steps; Phase 2 ZEPHYR topline data for ML-007C-MA in schizophrenia is due by mid-August 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6C1V5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","MPLT","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014021.USD","BK4585","LU2095319765.USD","SG9999014039.USD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645602919","title":"Maplight Therapeutics - Ml-004 Generally Well-Tolerated With No Severe or Serious Adverse Events in Phase 2 IRIS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645602919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645602919?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA4L4GD5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645402997","title":"Maplight Therapeutics - Phase 2 IRIS Trial Does Not Meet Primary Endpoint in Asd","url":"https://stock-news.laohu8.com/highlight/detail?id=2645402997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645402997?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA4L4GD5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645195029","title":"Maplight Therapeutics - to Engage With FDA in End-of-Phase 2 Meeting for Ml-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2645195029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645195029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA4L4GD5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029694","title":"Maplight Announces Topline Results From Phase 2 IRIS Study for Ml-004 in Autism Spectrum Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029694?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA4L4GD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644397430","title":"Maplight Therapeutics Inc: Setia Is Not Entitled to Receive Any Severance Payment in Connection With His Separation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644397430","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644397430?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:02","pubTimestamp":1781816550,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0UB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644039219","title":"Maplight Therapeutics - Jonathan Gillis to Continue as Principal Accounting Officer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644039219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644039219?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:02","pubTimestamp":1781816550,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0UB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644039215","title":"Maplight Therapeutics - Vishwas Setia Separated as CFO Effective Immediately on June 18, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644039215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644039215?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:02","pubTimestamp":1781816550,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644303929","title":"MapLight Therapeutics names Jonathan Gillis interim CFO after Vishwas Setia exit","url":"https://stock-news.laohu8.com/highlight/detail?id=2644303929","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644303929?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:01","pubTimestamp":1781816506,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics separated Chief Financial Officer Vishwas Setia, effective immediately on June 18, 2026, following a review of a human resources violation.The departure was described as unrelated to financial or operating results, internal controls, clinical programs, or financial reporting practices.Chief Administrative and Accounting Officer Jonathan Gillis was appointed interim chief financial officer, interim principal financial officer, effective June 18, 2026.Gillis will continue to serve as principal accounting officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval sy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1GWZzP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640949290","title":"MapLight Therapeutics Is Maintained at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2640949290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640949290?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:37","pubTimestamp":1780411020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2026 10:37 ET (14:37 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","SF"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":118,"code":"91000000","status":"200"}]}}